Google
×
We develop therapies for rare and ultrarare genetic diseases by exploring an array of drug modalities to select the best treatment strategy for each genetic ...
The Investor Relations website contains information about Ultragenyx Pharmaceutical Inc.'s business for stockholders, potential investors, and financial ...
People also ask
The Investor Relations website contains information about Regeneron Pharmaceuticals Inc.'s business for stockholders, potential investors, and financial ...
Missing: rare | Show results with:rare
Feb 15, 2024 · Financial and other information about Ultragenyx is routinely posted and is accessible on Ultragenyx's Investor Relations website (https://ir.
Find annual and quearterly earnings data for Ultragenyx Pharmaceutical Inc. Common Stock (RARE) including earnings per share, earnings forecasts at ...
RARE - Ultragenyx Pharmaceutical Inc. NasdaqGS ... Senior Director of Investor Relations & Corporate Communications ... rare and ultra-rare genetic diseases in ...
Feb 29, 2024 · A dedicated resource for shareholders and potential investors. · ASX Announcements · Quarterlies · Annual Reports · Presentations · Research Reports ...
Access all Takeda investor-related information including financial reports, earnings, quarterly reports, and IR events.
Welcome to our Investor and Media Centre. View our ... Lynas Rare Earths FY24 Half Year Presentation. 25 February 2024, Lynas Rare Earths FY24 Half Year Results.
Nov 2, 2022 · (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare ...